NUTLEY, N.J. and BASEL, Switzerland, June 22, 2011 /PRNewswire/ -- The Roche manuscript: "Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies" has been published in the prestigious Proceedings of the National Academy of Sciences of the USA (PNAS). Corresponding authors are Wolfgang Schaefer, Research Leader Molecular Biology in Biologics Research at Penzberg, and Christian Klein, Head of Oncology Programs, Discovery Oncology at Roche Glycart. Both are part of Roche's Pharma Research and Early Development (pRED) organization.
"It is encouraging to us that PNAS reviewers recognized the novelty of the approach for the generation of human bispecific, bivalent antibodies," note Wolfgang Schaefer and Christian Klein. "This technological breakthrough from pRED allowing generation and production of bispecific bivalent IgG antibodies that are very similar to conventional IgGs will prove a formidable benefit to patients."
The published paper describes a novel and generic approach to convert two given antibodies to human bivalent bispecific IgG antibodies that behave like standard monoclonal IgG antibodies in terms of target binding, stability and pharmacokinetics.
"Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies", PNAS online Early Edition (EE), http://www.pnas.org/content/early/recent.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at provid
Copyright©2010 PR Newswire.
All rights reserved